» Articles » PMID: 38867277

Therapeutic Potential of Exosomes Derived from Mesenchymal Stem Cells for Treatment of Systemic Lupus Erythematosus

Overview
Publisher Biomed Central
Date 2024 Jun 12
PMID 38867277
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune diseases are caused by an imbalance in the immune system, producing autoantibodies that cause inflammation leading to tissue damage and organ dysfunction. Systemic Lupus Erythematosus (SLE) is one of the most common autoimmune diseases and a major contributor to patient morbidity and mortality. Although many drugs manage the disease, curative therapy remains elusive, and current treatment regimens have substantial side effects. Recently, the therapeutic potential of exosomes has been extensively studied, and novel evidence has been demonstrated. A direct relationship between exosome contents and their ability to regulate the immune system, inflammation, and angiogenesis. The unique properties of extracellular vesicles, such as biomolecule transportation, biodegradability, and stability, make exosomes a promising treatment candidate for autoimmune diseases, particularly SLE. This review summarizes the structural features of exosomes, the isolation/purification/quantification method, their origin, effect, immune regulation, a critical consideration for selecting an appropriate source, and their therapeutic mechanisms in SLE.

Citing Articles

Application of mesenchymal stem cells in liver fibrosis and regeneration.

Liu Z, Ren J, Qiu C, Wang Y, Zhang T Liver Res. 2025; 8(4):246-258.

PMID: 39958916 PMC: 11771278. DOI: 10.1016/j.livres.2024.11.004.


Ingenol-3-Angelate Enhances the B Cell Inhibitory Potential of Mesenchymal Stem Cells, Leading to Marked Alleviation of Lupus Symptoms in MRL. Mice.

Lee H, Kim H, Kim J, Kim J, Park J, Kim M Int J Mol Sci. 2024; 25(23).

PMID: 39684336 PMC: 11641090. DOI: 10.3390/ijms252312625.

References
1.
Kim S, Lechman E, Bianco N, Menon R, Keravala A, Nash J . Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005; 174(10):6440-8. DOI: 10.4049/jimmunol.174.10.6440. View

2.
Cocucci E, Racchetti G, Meldolesi J . Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009; 19(2):43-51. DOI: 10.1016/j.tcb.2008.11.003. View

3.
Pisetsky D, Lipsky P . New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020; 16(10):565-579. PMC: 8456518. DOI: 10.1038/s41584-020-0480-7. View

4.
Miranda K, Bond D, McKee M, Skog J, Paunescu T, da Silva N . Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010; 78(2):191-9. PMC: 4451567. DOI: 10.1038/ki.2010.106. View

5.
van der Pol E, Coumans F, Grootemaat A, Gardiner C, Sargent I, Harrison P . Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost. 2014; 12(7):1182-92. DOI: 10.1111/jth.12602. View